{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:20:14Z","timestamp":1790439614527,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jchromb.2020.122176","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T13:11:17Z","timestamp":1589980277000},"page":"122176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies"],"prefix":"10.1016","volume":"1152","author":[{"given":"Eric D.","family":"Eisenmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.122176_b0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jchromb.2020.122176_b0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11523-019-00673-1","article-title":"Venetoclax: A review in relapsed\/refractory chronic lymphocytic leukemia","volume":"14","author":"Scott","year":"2019","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jchromb.2020.122176_b0015","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jchromb.2020.122176_b0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MOH.0000000000000560","article-title":"Hypomethylating agents with venetoclax: have we discovered the holy grail?","volume":"27","author":"Gutman","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.jchromb.2020.122176_b0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122176_b0030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122176_b0035","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/jcph.730","article-title":"Evaluation of Rifampin\u2019s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study","volume":"56","author":"Agarwal","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122176_b0040","unstructured":"AbbVie, Venclexta\u00ae (Venetoclax tablets): US prescribing information, (n.d.)."},{"key":"10.1016\/j.jchromb.2020.122176_b0045","unstructured":"F.D.A.C. for D.E. and Research, Application Number: 208573Orig1s000. Pharmacology Review(s), (n.d.). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208573Orig1s000PharmR.pdf."},{"key":"10.1016\/j.jchromb.2020.122176_b0050","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2020.122176_b0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic","author":"Roberts","year":"2016","journal-title":"Leukemia, N. Engl. J. Med. 374"},{"key":"10.1016\/j.jchromb.2020.122176_b0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/13543784.2017.1386173","article-title":"Venetoclax for the treatment of chronic lymphocytic leukemia","volume":"26","author":"Gentile","year":"2017","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.jchromb.2020.122176_b0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.jchromb.2020.122176_b0070","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122176_b0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","article-title":"Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics","volume":"74","author":"Freise","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2020.122176_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12739","article-title":"Semi-mechanistic modeling to guide venetoclax coadministration with ritonavir and digoxin","author":"Alhadab","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2020.122176_b0085","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","article-title":"Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin\u2019s lymphoma patients: a pooled population pharmacokinetic analysis","volume":"18","author":"Jones","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.jchromb.2020.122176_b0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.jchromb.2020.122176_b0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dmpk.2019.11.004","article-title":"Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters","volume":"35","author":"Nozaki","year":"2020","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2020.122176_b0100","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s12325-018-0793-y","article-title":"Effect of azithromycin on venetoclax pharmacokinetics in healthy volunteers: implications for dosing venetoclax with P-gp inhibitors","volume":"35","author":"Agarwal","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jchromb.2020.122176_b0105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jchromb.2020.122176_b0110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2020.122176_b0115","article-title":"Murine pharmacokinetic studies","volume":"8","author":"Leblanc","year":"2018","journal-title":"Bio-Protoc."},{"key":"10.1016\/j.jchromb.2020.122176_b0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1570-0232(04)00666-X","article-title":"Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography\u2013mass spectrometry","volume":"811","author":"Tohnya","year":"2004","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.jchromb.2020.122176_b0135","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1124\/dmd.109.029397","article-title":"Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam","volume":"37","author":"van Waterschoot","year":"2009","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.jchromb.2020.122176_b0140","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5530\/jyp.2018.10.87","article-title":"Evaluation of deuterium-labeled internal standard for the measurement of venetoclax by HPLC-ESI -tandem mass spectrometry","volume":"10","author":"Inturi","year":"2018","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.jchromb.2020.122176_b0145","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1172\/JCI33435","article-title":"Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism","volume":"117","author":"van Herwaarden","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jchromb.2020.122176_b0150","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","article-title":"Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins","volume":"94","author":"Schinkel","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jchromb.2020.122176_b0155","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1124\/dmd.108.020594","article-title":"Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds","volume":"36","author":"Chen","year":"2008","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220305286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220305286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:03:37Z","timestamp":1761606217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023220305286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":29,"alternative-id":["S1570023220305286"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122176","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122176"}}